China Isotope & Radiation Corporation’s (CIRC) subsidiary, HTA Co., Ltd. (HKG: 1763), has announced that it has received marketing approval from the National Medical Products Administration (NMPA) for its sodium fluoride [18F]. This product is primarily utilized in positron emission tomography (PET) to identify areas of altered osteogenic activity in bone imaging, marking a significant advancement in the field.
The product is celebrated as the first domestically developed PET imaging agent for bone imaging in China, enabling early, accurate, and non-invasive diagnosis of bone metastasis. Sodium fluoride [18F] PET or PET/CT whole-body bone imaging offers a higher sensitivity method that can detect small bone metastases at an earlier stage. Its fast blood clearance also reduces the waiting time for patients, streamlining the diagnostic process. – Flcube.com
